Tirzepatide attenuated alcohol reward, reduced voluntary drinking, prevented binge and relapse-like behaviors, and induced lasting changes in lateral septum signaling in rodents.
Blocked relapse (p<0.001)Tirzepatide prevented relapse-like drinking after alcohol deprivation and maintained efficacy during repeated dosing
What the researchers found
Tirzepatide attenuated alcohol reward (dopamine release p<0.001), dose-dependently reduced intake (p<0.001), prevented binge (p<0.01) and relapse drinking (p<0.001), with sustained efficacy, and induced lasting synaptic depression and histone changes in the lateral septum.
Why it matters
This is the most comprehensive preclinical study of a GLP-1/GIP agonist for alcohol use disorder, providing both behavioral and mechanistic evidence that could support human clinical trials.
How the study worked
Comprehensive rodent behavioral battery (locomotor activity, CPP, two-bottle choice, drinking in the dark, alcohol deprivation effect), microdialysis, electrophysiology, and proteomics in the lateral septum.
What this study cannot tell us
Rodent models; alcohol consumption patterns differ from human AUD. Lateral septum mechanisms need human validation. Cannot determine relative contributions of GLP-1R vs GIPR agonism.
How to read the evidence
Comprehensive preclinical study with behavioral, neurochemical, electrophysiological, and proteomic evidence. Strong preclinical case for human trials.
When this study was published
Published in 2025.
The bigger picture
Tirzepatide is already FDA-approved for diabetes and obesity. These findings position it for potential repurposing for alcohol use disorder, with the advantage of simultaneously addressing metabolic complications of heavy drinking.
Questions still open
- Will tirzepatide reduce alcohol consumption in human clinical trials?
- Is the lateral septum the primary brain target, or do other regions contribute?
- Does GIP receptor agonism add benefit over GLP-1 alone for AUD?
Common questions
Could tirzepatide help people stop drinking?
How does an obesity drug reduce alcohol drinking?
Read the original research
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
EBioMedicine, 124, 106119
Citation
Edvardsson, Christian E; Adermark, Louise; Gottlieb, Sam; Alfreji, Safana; Emous, Thaynnam A; Gouda, Yomna; Thorsell, Annika; Vujičić, Milica; Aranäs, Cajsa; Benrick, Anna; Wernstedt Asterholm, Ingrid; Lopez, Marcelo F; Becker, Howard C; Jerlhag, Elisabet. (2026). Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.. EBioMedicine, 124, 106119. https://doi.org/10.1016/j.ebiom.2025.106119